Dan Ahrens argues cannabis rescheduling is an administrative process unaffected by election outcomes, while psychedelic stocks overreacted to Otsuka's NDA filing.
Summary
Dan Ahrens discusses the recent Schwab Impact Conference, noting that cannabis rescheduling is an administrative process handled by the DOJ and Administrative Law Judges, making it immune to legislative stalemate in Congress. He highlights that the upcoming hemp ban is driving revenue growth for licensed dispensaries by capturing displaced market share. Regarding psychedelics, Ahrens argues the recent selloff following Otsuka’s New Drug Application (NDA) filing was an overreaction, as the nonprofit entity lacks commercial infrastructure and must navigate existing patents held by competitors like Compass Pathways. He also clarifies that cannabis ETFs using total return swaps can exceed 100% exposure without incurring margin debt or interest payments.
Episode sections
- 0:30 – 3:17
Schwab Impact Conference Highlights
Dan Ahrens discusses attending the Schwab Impact conference, noting significant interest from independent RIAs and press in cannabis and psychedelics. He emphasizes that education is required because many advisors are unaware of recent regulatory progress, such as the Administrative Law Judge (ALJ) ruling.
- 3:17 – 7:00
Election Impact and Legislative Stalemate
Ahrens predicts a divided government with Democratic control of the House and a tight Senate race, leading to legislative stalemate. He argues this is positive for cannabis because rescheduling is an administrative process handled by the DOJ and ALJ, not Congress, making the Safe Banking Act less critical for immediate progress.
- 7:00 – 10:35
Hemp Ban and Cannabis Market Growth
The speakers discuss the upcoming hemp ban deadline, noting that licensed cannabis dispensaries are capturing demand previously held by the hemp sector. Ahrens highlights that this incremental revenue growth strengthens the sector's fundamentals ahead of potential rescheduling.
- 10:35 – 12:07
ETF Structure and Margin Misconceptions
Ahrens clarifies that cannabis ETFs using total return swaps can have exposure greater than 100% without incurring margin debt or interest payments. He advises investors not to interpret high exposure percentages as financial risk similar to a retail margin account.
- 12:07 – 18:01
DEA Dual License Ruling
The DEA has rejected dual licenses for medical and adult-use cannabis at the same physical location. Ahrens suggests creative physical solutions, such as separate entrances, to comply with the ruling while maintaining operations.
- 18:01 – 22:44
Psychedelic Sector Selloff and Otsuka Filing
Ahrens analyzes a recent selloff in psychedelic stocks following Otsuka’s filing of a New Drug Application (NDA) for psilocybin. He argues the market overreacted, noting that Otsuka is a nonprofit that will need commercial partners and must navigate existing patents held by competitors like Compass Pathways.
Claims worth verifying
The Democratic party is widely believed to gain control of the House, with the Senate being a toss-up or leaning Democrat, resulting in legislative stalemate.
Unidentified speaker ·4:30
How to verify: Check post-election results for the 2026 US House and Senate elections.
Cannabis rescheduling is in the hands of the Administrative Law Judge (ALJ), DOJ, and Attorney General, not Congress.
Unidentified speaker ·5:48
How to verify: Review the DEA rescheduling docket and the ALJ's final recommendation document.
The hemp ban is causing licensed cannabis dispensaries to capture demand previously held by the hemp sector.
Unidentified speaker ·15:05
How to verify: Analyze quarterly revenue reports of major licensed cannabis operators for growth correlated with hemp ban timelines.
Cannabis ETFs using total return swaps do not pay margin interest or owe money based on exposure percentages over 100%.
Unidentified speaker ·10:35
How to verify: Review the prospectus and regulatory filings of cannabis ETFs (e.g., AdvisorShares) detailing their use of total return swaps.
The DEA rejected dual licenses for medical and adult-use cannabis at the same physical location.
Unidentified speaker ·12:07
How to verify: Check DEA press releases or official correspondence regarding medical marijuana dispensary registrations.
Otsuka filed a New Drug Application (NDA) with the FDA for psilocybin to treat depression.
Unidentified speaker ·18:01
How to verify: Search the FDA Drug Development and Approval Process database for Otsuka’s NDA submission.
Otsuka is a nonprofit organization.
Unidentified speaker ·19:18
How to verify: Check Otsuka’s corporate structure and IRS tax-exempt status documentation.
Compass Pathways holds patents that Otsuka must navigate for psilocybin treatment.
Unidentified speaker ·19:18
How to verify: Search USPTO patent databases for Compass Pathways’ intellectual property holdings related to psilocybin.
Compass Pathways stock was down significantly but recovered the day after the Otsuka news.
Unidentified speaker ·18:01
How to verify: Check historical stock price data for Compass Pathways (CMP) around the date of the Otsuka NDA filing.
Compass Pathways was up approximately 30% for the year at the time of the interview.
Unidentified speaker ·22:09
How to verify: Calculate the year-to-date performance of Compass Pathways (CMP) stock as of November 2026.
Do your own research
- Review the specific Administrative Law Judge (ALJ) ruling details and the current status of the DOJ’s review process for cannabis rescheduling.
- Verify the timeline and specific provisions of the upcoming hemp ban to assess the volume of displaced market share.
- Examine the prospectus of cannabis ETFs to understand the mechanics of total return swaps and confirm whether margin debt is incurred.
- Analyze the DEA’s ruling on dual licenses to determine compliance requirements for operators holding both medical and adult-use permits.
- Read Otsuka’s New Drug Application (NDA) filing and press releases to understand their partnership strategy and commercialization plans.
- Review patent portfolios of Compass Pathways and other competitors to assess potential IP barriers for Otsuka’s psilocybin development.
- Check historical market performance data for November and December to validate the seasonality claims made by the speaker.
Full transcriptexpand
- 0:05
- Unidentified speaker: everyone and welcome back to another exciting advisor for Zelfnooner.
- 0:09
- Unidentified speaker: Today we're excited to be sitting down with Dan Ahrens, spending some time on talking through the themes that matter with a special focus today on all things related to cannabis and psychedelic biotech.
- 0:18
- Unidentified speaker: So should be a good one.
- 0:19
- Unidentified speaker: A lot of great stuff going on in both of these spaces, a lot of interesting stuff to really understand and understand whether you're kind of following the space from an educational perspective, you're an investor, all of that.
- 0:28
- Unidentified speaker: So we'll get into it today.
- 0:30
- Unidentified speaker: But um before we jump in and start, um, welcome back.
- 0:33
- Unidentified speaker: I know you've been on quite a conference tour lately, just getting back from Schwab Impact.
- 0:37
- Unidentified speaker: Any quick highlights to pull out from that conference?
- 0:40
- Unidentified speaker: I know that's a big one for advisors.
- 0:42
- Unidentified speaker: And a quick reminder to people uh I am hanging around a conference at Schwab Impact.
- 0:47
- Unidentified speaker: I also have my computer with me and I am working on the funds the entire time.
- 0:52
- Unidentified speaker: So Schwab Impact is a uh very very big conference.
- 0:56
- Unidentified speaker: I guess it's probably the biggest investor or advisor conference uh that exists in the world.
- 1:03
- Unidentified speaker: I talked to quite a bit of press I talked to the Wall Street Journal I talked to Reuters and you know a lot of that is education, educating them on what is actually going on in the world of cannabis because reminder that people have heard me say before the way cannabis has gone over the last five years or so a lot of people aren't really up to speed.
- 1:26
- Unidentified speaker: They hear bits and pieces about this ALJ what the heck does that mean?
- 1:31
- Unidentified speaker: What's the real status?
- 1:33
- Unidentified speaker: Isn't this just more of the same so people outside of our uh world if we want to call it that need a lot of education.
- 1:41
- Unidentified speaker: The same thing with a lot of investment advisors.
- 1:44
- Unidentified speaker: So an awful lot of independent RIAs custody and clear through Schwab and so there's a lot of different uh walks of life investment advisors out there some pretty darn big ones too and and you know what um interest a fair amount of interest in cannabis and in psychedelics they also love the story about HVAC uh but that was more of a of a story and uh and and educating again but uh it was an intriguing intriguing amount of interest from investment advisors and uh you know other people in the press that were stopping by randomly um in psychedelics and cannabis a lot more open-mindedness if we will love to hear it I feel like that's great.
- 2:33
- Unidentified speaker: I mean I know you know through all these conferences over the years we've kind of put out that message tried to provide education to advisors on all of the fronts you know I think whatever questions they come up with but I think it's kind of an interesting comparing this year's to last year's where we've gotten so much progress in terms of cannabis especially with medical cannabis getting rescheduled um obviously potentially what we're you know anticipating I think for uh recreational use really interesting time to kind of really learn more of course the volatility still remains you're giving everyone warnings on uh the volatility side of things but um yeah I think a really interesting time to kind of get an understanding of kind of where we are and I know we'll dig into it I did want to spend just a little bit of time before we kind of work through um kind of where we are in cannabis and you know looking ahead to important dates like the fifth coming up this week.
- 3:17
- Unidentified speaker: But I know it is also election day and that is a big one.
- 3:20
- Unidentified speaker: Obviously a lot hangs in the balance across a lot of different um things but was just curious in terms of you know high level do you have any thoughts in terms of the election and then kind of zooming in for cannabis specifically I know there's a lot of focus on the Massachusetts uh kind of change there's been a kind of push to un-reschedule cannabis for that state again I think it seems like you know pretty widely um unpopular and supported I guess by a small group of kind of prohibitionists um but just curious to get your takes in terms of election day how it applies to markets and of course cannabis um well let's talk about cannabis first uh because that's where most uh interest of listeners is yeah there's there's a few pockets of of positive things around the country nothing negative nothing's getting removed in cannabis except uh we're we're still headed towards the hemp lockdown if we want to call it that um but yeah there's some New Hampshire there's some some pockets of there's always incremental progress when it comes to cannabis but let's zoom out and look at the um election overall it's uh widely believed that the um democratic party is going to get good control of the House and it seems in most places like the Senate is much of a toss up at this point but it could also be leaning uh Democrat and uh do you know what this means it means stalemate for the next two years stalemate on everything like we've had pretty good stalemate over the last two years anyway it's been freaking ridiculous that uh the Senate won't budge from wanting to have uh 60% uh to get anything uh remotely remotely controversial pass they're all very very uh wimpy and um trying to make the whole uniparty happy all the time so no there's some um democrats are gonna get control of the house probably maybe a uh a a control of the senate by one position 51 to 49 we'll see but they're not gonna pass anything either you they're not gonna have 60 control of that of the of the Senate and the White House will veto anything they want to veto so what we're talking about is stalemate.
- 5:48
- Unidentified speaker: Now McKenzie what does that mean for cannabis practically prisons as usual I would imagine I think it still keeps moving forward but I I don't know I mean it kind of throws it into a fruit yeah if they really need to pass a safe banking act they can probably get it passed um but I don't even know if we need a safe banking act because the um the rescheduling is completely out of the hands of the House and Senate I could care zero about what the House and Senate thinks about cannabis at this point because it's completely in the hands of the administrative law judge and the process with the DOJ Attorney General and so on.
- 6:30
- Unidentified speaker: We may or may not need safe banking and I don't care much.
- 6:34
- Unidentified speaker: The other thing is markets overall is a divided White House and House and Senate good or bad for the markets it ain't bad.
- 6:45
- Unidentified speaker: It it really isn't bad.
- 6:48
- Unidentified speaker: It can a lot of people are seeing it as a potential positive and uh once again we're gonna have a lot of stalemate over the next two years and that is just fine.
- 7:00
- Unidentified speaker: Yeah we've been there before I think uh seasonality wise also November December tend to be really strong so I imagine you know even if that gets dampened slightly you know potentially from historical you know terms I think things have been pretty solid we've been there before um but yeah interesting I think as it relates to cannabis I am curious we're nearing that one month off or yeah one month off deadline you mentioned for hemp I feel like I've seen all of the ads come out saying we're dumping inventory we're making this move I'm curious you know do you have any thoughts that that actually goes through obviously it's hard to predict um I don't know what are your thoughts we we've heard all along it I mean there's a few lifelines being thrown out there to you know please save it um and again anybody that's saying is is for if we had level playing field regulated as one plant put everybody under the same rules but no that's not really gonna happen bans are coming into effect and uh as you said a lot of those people are dumping inventory and uh you know they're they're they're facing the writing on the wall at the same time um there's a lot of hopefulness uh about the rescheduling and I have always been one to say I am very excited about the announcement yes I realize there's a 25 day cooling off period yes I realize there's gonna be objections to it still from you know the the loud screaming prohibitionists that stamp their feet um but the announcement from the ALJ I was about to say judge but that would be no it's the administrative law judge um is what I am very hopeful for.
- 8:41
- Unidentified speaker: I think that's gonna be a nice uh uh boost to the stocks that we invest in in cannabis even though there's still gonna be steps and when I say there's steps that also means there's volatility people we have never said there's not these are uh still right now OTC traded stocks for the most part and uh they're volatile as hell we're still talking about cannabis stocks that move on regulatory announcements that is not normal stock investing people anybody that thinks it is shouldn't be investing in this stuff.
- 9:20
- Unidentified speaker: Yeah so uh plenty of volatility but I am cautiously optimistic people love that term don't they're it's a I mean it's a good one I think it holds up but yeah I definitely agree anything that's sort of investing that's something that's pushing the frontier that is you know making a big big change obviously volatility tends to kind of accompany that um but again like you mentioning hoping hoping that we see on the other side of rescheduling kind of things really turn around obviously as this process is moving its way through we've seen that volatility some positive obviously as we you know kind of more recently have seen you know generally a lot of cannabis stocks get responsive to the fact that there was uncertainty to some degree just like delays but those are working their way through I think we've seen a lot of the names in cannabis you know have some really strong green days lately which has been fantastic.
- 10:04
- Unidentified speaker: We've seen great news I know the DEA kind of issuing the medical dispensary registrations has been a real positive and a real kind of sign that things are moving in that direction.
- 10:12
- Unidentified speaker: It's all moving along uh yeah and you know stock prices are up really nicely today and they were yesterday as well we see that as a good positive but um gosh over the last couple of weeks they were beat down pretty much again so it's it's disconcerting as hell the price points that we're starting at right now still or we're starting at in the past week so no that's not lost on us.
- 10:35
- Unidentified speaker: And one other thing I want to address for for those that are listening um some people look at the holdings of the the large cannabis fund and and they see you know well does it have positive cash does it have negative cash and I want to express to people that it doesn't really matter if a cannabis fund managed by us or anybody else is a little bit overexposed if it owns you know 101% exposure or 102% exposure.
- 11:05
- Unidentified speaker: This ain't your your Robinhood account people funds don't pay margin there's there's no margin in an in a in an ETF um you know especially ETFs uh in cannabis uh with us and you know other companies out there use total return swaps um those are derivative products no there's no deficit there is no amount of money that's owed there's no amount of money that needs to be paid back and it sure as hell isn't paying margin interest anything like that no so I want to set people uh you know to be calm and um the fund can invest like it invests that's all yeah I think that's good good education good reminders I think especially as we're kind of gearing up into a time that hopefully again we're seeing progress come through and I feel like some of those same questions tend to crop up when we see big cannabis news hit because hopefully it means you know people who are outside like you're mentioning the cannabis world kind of you know take a peek in and see what's going on.
- 12:07
- Unidentified speaker: So I think that's important education.
- 12:09
- Unidentified speaker: Um I am curious psychedelics sorry I do I do want to talk about psychedelics I do first want to talk about um for cannabis with the um medical dispensary registrations I am curious what you're thinking about sort of the dual license issue and kind of what that creates for um you know companies what are your thoughts in terms of that sort of split no it it's interesting and you know at first everybody thought like oh no that's a negative uh the DEA is turning things down no they're they're doing their job actually it's uh administrative type stuff and again we started with the fact that they are going through these applications and a process kind of implying that they expect everything to be rescheduled right Mackenzie yeah so they're doing their jobs so what they said for those that don't know is they turned down some dual licenses and that means you have a dispensary dispensary store that would have a license for medical and a license for adult use and for for those that walk into dispensaries that should know this kind of stuff usually they have two different lines they might have a little divider down the middle or just a piece of that you know ribbon like you see in the movie theaters and stuff because um prices are different because taxes are different and if you have a medical card you get uh a different price than if you don't have a medical card that's why that exists so the DEA turned it down that no you can't be dual you can't have the same thing under in one roof um which shouldn't surprise everybody too much DEA administrative people doing their jobs I I did see a very good suggestion that might work is um you know doing a little bit of a build out so the same address the same brick and mortar building maybe it needs to have two different entrances maybe it needs to have hey in Texas I see this in liquor stores sometimes on you can't sell liquor on on Sundays but they have one door that sells beer and wine a different door that sells all the other stuff and or they they uh you know take out the divider and open the garage doors whatever the hell they do so that was a suggestion that might work for this dilemma um we might have two different doors or somehow dividing up the dispensary uh a little bit more than just the little velvet rope.
- 14:37
- Unidentified speaker: Fair enough hopefully some creative thinking but I guess in the long term again I think hoping and anticipating full rescheduling a lot of those kind of crazy workarounds will work themselves out which is great.
- 14:48
- Unidentified speaker: All right well I know we do want to talk psychedelics but I guess rounding out the cannabis conversation I know we're in the middle of earnings so things are kind of working themselves out there.
- 14:55
- Unidentified speaker: Also some interesting kind of MA deals still continuing to work themselves out.
- 14:59
- Unidentified speaker: So definitely something that we're kind of keeping an eye on um but I don't know if we have any particular kind of thoughts or comments you want to add there.
- 15:05
- Unidentified speaker: But um yeah I think just really interesting I think the one positive thing that I think I've tended to see around earnings and kind of just around this time is kind of falling on on the hemp conversation um how much not how much that the uh legal market for cannabis has drawn in certain states some of that um kind of shut down shuttered hemp again I know it's a range but uh has kind of drawn in some of that demand which has been great in terms of growth for cannabis so hopefully we continue yeah no we we we we've seen positive news about the growth and revenues as uh licensed dispensaries are already starting to realize some of the hemp uh shut down business it's a good thing it it's all there's you know we see incremental positive news after incremental positive news and none of it matters while we're waiting on the rescheduling the rescheduling is the big one but you know we we have to keep in the back of our minds that the rescheduling could lay an egg if we did not I mean in a bad way I'm trying to look for a saying here if we didn't have that incremental growth if we didn't have uh the hemp band on the way if we didn't have positive uh revenue and continued growth state by state and we realize that 280e is going to go away all these different incremental things if the companies were fucking then the rescheduling might not have the impact that we're all hoping for but that's not the case we're seeing good sales good growth state by state incremental positive changes and that's why we're all very excited for the rescheduling that's still coming.
- 16:50
- Unidentified speaker: That's fair.
- 16:51
- Unidentified speaker: Well keeping an eye on the fifth I know it's not the make or break it's the deadline ultimately but hopefully we get some news and information around there we will wait and see.
- 16:57
- Unidentified speaker: So very exciting stuff coming looking forward to touching base next next um you know next little while um all right well then turning to psychology on one on one risk though I'm sorry to interrupt on one risk is there's not a fixed timeframe for um a ruling yeah from the administrative law judge but to remind everybody each time they he has responded it's been very quick there's been multiple deadlines and he has been very quick to respond after those deadlines and yeah some were a little bit disappointing because it was an additional uh stay or an additional um you know deadline in the future and it really really seems like it's virtually impossible to have another delay it really seems like this is it with the wording of the last one and we hope or expect him to say something very quickly uh on or after November 5th.
- 17:56
- Unidentified speaker: Okay.
- 17:56
- Unidentified speaker: I think you're right just in case I'm gonna knock on wood.
- 17:59
- Unidentified speaker: We'll see.
- 17:59
- Unidentified speaker: But yes no I think that sounds good things are moving along which is great.
- 18:01
- Unidentified speaker: Thanks uh to Judge Julius um okay let's talk psychedelics really quickly I feel like there's been you we were talking before uh we went on you know a lot going on in that space it's had a great year but um tell us about what's happened in kind of the past you know week ultimately huge news yesterday huge and it cratered um psychedelic stocks really across the board just about um so people need to to read up on it know what happened it is Osuna USONA files psilocybin for depression n d a that's um new drug application that's what the NDA is in this case um and then they're basically in a race with compass compass pathways who's gonna get it first so uh compass pathways was way down yesterday it's up really nicely today um in portfolios I was a buyer of compass pathways and a number of other psychedelic stocks yesterday because I personally thought the news was way way overdone so everybody needs to read up on it what is uh Osuna Osuna I feel like they all have kind of crazy names a little bit I feel like they're meant to be read and not spoken all the time but yes that's fair.
- 19:18
- Unidentified speaker: So um yeah they filed an application with the FDA for a new drug application um basically for treatment resistant depression or major depressive disorder and uh it was way way overdone in the in the marketplace because you know I just gotta say on the surface what's a nonprofit going to do with a drug approval um they're gonna need somebody to sell it they're gonna need someone to market it and we've always said even if compass pathways was the winner of the first approval what about all the other companies that have stuff in FDA trial for LSD ketamine ibocaine mdma all the other treatments all the different patents and even this uh nonprofit Osuna needs to find some work around for the patents that um uh compass pathways owns so if you step back a minute and say okay we have a nonprofit working in psychedelics that's moving things along through FDA approval process isn't that positive for all psychedelics think about it I mean and when you think about drugs and treatments I don't know we have big pharma and healthcare it's a for-profit business it's a for-profit business it has to be yeah uh the way things work so big overreaction yesterday uh in psychedelics really big and but a major drop down reminder these things are volatile as hell especially when you tag on the fact that they trade like biotech stocks I've all said that they trade based on their intellectual property the value of their intellectual property and where they stand at FDA trial so seeing a really nice bounce back today um glad we were a buyer yesterday big overreaction of news in the psychedelic space.
- 21:22
- Unidentified speaker: Okay I think it's good to see I I definitely think your point on um one I think a lot of different IP from a lot of these different companies you know it's definitely not one shoe fits all even on a specific compound in terms of duration in terms of effects all these different things so I think there's yeah room to play uh for a lot of these companies there and then of course again like you mentioned so many different types of psychedelic related compounds out there that some of these companies are working on all being I think supported by um you know uh sort of the institutions that are putting them forward we've talked about the FDA fast tracking all these things um I think pushing in the right direction you know for compass even I know you're mentioning is up today I was looking at it this morning before Market Open and despite it being down like you're saying uh you know pretty pretty healthily I think it was still up for the year you know something like 30 you know a little over 30% something like that.
- 22:09
- Unidentified speaker: So again I think it just speaks to how well these companies have done um and kind of the the future that they're building really compelling.
- 22:16
- Unidentified speaker: It'll be interesting to see again if we see more MA especially from big pharma.
- 22:20
- Unidentified speaker: I know we have uh I think Advi or not Advi um uh Novonordisk is coming up in earnings I feel like you know really interesting to kind of hear what they're looking at as well.
- 22:29
- Unidentified speaker: Um but yeah definitely a space to watch I think that sounds good absolutely um all right well then Dan thanks for taking the time really appreciate it great to check in on these specific themes uh I think a lot to uncover and a lot to pay attention to so appreciate the time and we will catch you soon
More from AlphaNooner by AdvisorShares
AlphaNooner - A Veteran’s Journey Through Trauma & Psychedelic Medicine with Graham Ginn
Episode discussion: Veteran Graham Ginn discusses psychedelic medicine, trauma healing, and legislative advocacy for psilocybin research.
Speakers’ claims: Graham Ginn, a Navy veteran, shares his transition from skepticism to advocacy for psychedelic medicine after a transformative experience during a mental health crisis. He recounts using plant entheogens to cope with a stage four throat cancer diagnosis, claiming the substances aided in pain management and psychological resilience. Ginn highlights legislative efforts such as Texas HB 1802 and the federal Freedom to Heal Act as key vehicles for descheduling and research. The discussion emphasizes the importance of professional integration, medical screening for drug interactions, and the distinction between regulated therapy and unlicensed facilitation.
AlphaNooner - Cannabis After the 2026 Midterms: What Changes? with Todd Harrison
Episode discussion: Todd Harrison argues 2026 midterms and DEA rescheduling will drive cannabis sector consolidation and profitability.
Speakers’ claims: Todd Harrison argues that the 2026 midterm elections defeated prohibitionist efforts in states like Massachusetts and Idaho, while opening new markets in Pennsylvania and Wisconsin. He anticipates a positive DEA decision to reschedule cannabis from Schedule I to Schedule III, which would restore IRS Section 280E tax deductions and significantly improve company profitability. Harrison identifies the December 11th intoxicating hemp ban as a catalyst that will drive consumers back to regulated dispensaries. He expects 2027 to be a 'show me year' for double-digit growth as the market consolidates around fewer, larger players. Harrison highlights Village Farms and TerrAscend as undervalued opportunities relative to peers like Aurora.